+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin-fibrate combination: therapy for hyperlipidemia: a review



Statin-fibrate combination: therapy for hyperlipidemia: a review



Current Medical Research and Opinion 19(3): 155-168



Statins and fibrates are well-established treatments for hyperlipidaemias and the prevention of vascular events. However, fibrate + statin therapy has been restricted following early reports of rhabdomyolysis that mainly involved gemfibrozil, originally with bovastatin, and recently, with cerivastatin. Despite this limitation, several reports describing combination therapy have been published. This review considers these studies and the relevant indications and contraindications. Statin + fibrate therapy should be considered if monotherapy or adding other drugs (e.g. cholesterol absorption inhibitors, omega-3 fatty acids ornicotinic acid) did not achieve lipid targets or is impractical. Combination therapy should be hospital-based and reserved for high-risk patients with a mixed hyperlipidaemia characterised by low density lipoprotein cholesterol (LDL) >2.6 mmol/l(100 mg/dl, high density lipoprotein cholesterol (HDL) <1.0 mmol/l (40 mg/dl) and/or triglycerides> 5.6 mmol/l (500 mg/dl. These three 'goals' are individually mentioned in guidelines. Patients should have normal renal, liver and thyroid function tests and should not be receiving therapy with cyclosporine, protease inhibitors or drugs metabolised through cytochrome P450 (especially 3A4). Combination therapy is probably best conducted using drugs with short plasma half-lives; fibrates should be prescribed in the morning and statins at night to minimise peak dose interactions. Both drug classes should be progressively titated from low doses. Regular (3-monthly) monitoring of liver function and creatine kinase is required. In conclusion, fibrate + statin therapy remains an option in high-risk patents. However, long-term studies involving safety monitoring and vascular endpoints are required to demonstrate the efficacy of this regimen.

(PDF emailed within 0-6 h: $19.90)

Accession: 050378529

Download citation: RISBibTeXText

PMID: 12814127

DOI: 10.1185/030079903125001668


Related references

Safety and efficacy of fibrate-statin combination therapy compared to fibrate monotherapy in patients with dyslipidemia: a meta-analysis. Vascular Pharmacology 65-66(): 23-30, 2015

Is combined statin and fibrate therapy indicated in the management of mixed hyperlipidemia?. Presse Medicale 27(15): 720-722, 1998

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. American Journal of Cardiology 89(4): 390-394, February 15, 2002

Statin-fibrate combination therapy. Annals of Pharmacotherapy 35(7-8): 908-917, July-August, 2001

Statin-fibrate combination therapy. American Journal of Cardiology 101(10): 1521-1521, 2008

Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiology and Drug Safety 21(5): 470-484, 2012

Combination statin-fibrate therapy: safety aspects. Diabetes, Obesity & Metabolism 11(2): 89-94, 2008

Do persons with diabetes benefit from combination statin and fibrate therapy?. Current Cardiology Reports 14(1): 112-124, 2012

Do persons with stroke benefit from statin-fibrate combination therapy?. European Journal of Internal Medicine 26(2): 148-149, 2015

Efficacy and safety of statin and fibrate combination therapy in lipid management. Diabetes & Metabolic Syndrome 6(3): 173-174, 2013

Combination fibrate-statin therapy for the treatment of severe hypertriglyceridaemia in renal disease. International Journal of Clinical Practice 57(3): 249-251, 2003

Long-term safety of fibrate-statin combination therapy in the treatment of hypercholesterolaemia. British Journal of Clinical Pharmacology 37(5): 511P, 1994

Treatment of combined hyperlipidemia: fibrate and/or statin?. Revue Medicale de Liege 54(7): 583-587, 1999

The effect of fibrate-statin combination therapy on cardiovascular events: a retrospective cohort analysis. Current Medical Research and Opinion 26(9): 2141-2146, 2010

Statin-fibrate combinations in patients with combined hyperlipidemia. Atherosclerosis 155(1): 263-264, March, 2001